PECAM1 plays a role in the pathogenesis and treatment of bone metastases

Frontiers in Genetics

Genetics

Jia-Ke Li¹  Jiong Li²  Chao-Feng Guo²  Zhuo-Tao Liang²  Hao Tang²  Hong-Qi Zhang² 

[1] Department of General Surgery, The Third Xiangya Hospital of Central South University, Changsha, China;Department of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, China;National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China;

关键词: PECAM1;    bone metastasis;    osteoclast;    breast cancer;    prostate cancer;    biomarker;   

DOI  :  10.3389/fgene.2023.1151651

 received in 2023-01-26, accepted in 2023-03-06,  发布年份 2023

来源: Frontiers

【 摘 要 】

Bone is the third most common metastatic site for all primary tumors, the common primary focus of bone metastases include breast cancer, prostate cancer, and so on. And the median survival time of patients with bone metastases is only 2–3 years. Therefore, it is urgent to develop new targets to diagnose and treat bone metastases. Based on two data sets GSE146661 and GSE77930 associated with bone metastases, it was found that 209 genes differentially expressed in bone metastases group and control group. PECAM1 was selected as hub-gene for the follow-up research after constructing protein-protein interaction (PPI) network and enrichment analysis. Moreover, q-PCR analysis verified that the expression of PECAM1 decreased in bone metastatic tumor tissues. PECAM1 was believed to be possibly related to the function of osteoclasts, we knocked down the expression of PECAM1 with shRNA in lymphocytes extracted from bone marrow nailed blood. The results indicated that sh-PECAM1 treatment could promote osteoclast differentiation, and the sh-PECAM1-treated osteoclast culture medium could significantly promote the proliferation and migration of tumor cells. These results suggested that PECAM1 may be a potential biomarker for the diagnosis and treatment of bone metastases of tumor.

【 授权许可】

Unknown   
Copyright © 2023 Liang, Li, Li, Tang, Guo and Zhang.